Introduction
============

As a highly aggressive neoplasm, esophageal cancer is the ninth most common malignancy and the sixth most common cause of cancer death throughout the world.[@b1-ott-9-5663] Adenocarcinoma and squamous cell carcinoma are the principal histological types of esophageal cancer.[@b2-ott-9-5663] Over the past three decades, the incidence of adenocarcinoma has increased in the US and Europe. Nevertheless, esophageal squamous cell carcinoma (ESCC) is still the dominant histological type around the world, which accounts for \>95% of esophageal cancers in the People's Republic of China.[@b3-ott-9-5663] Esophageal cancer is often diagnosed at a very advanced stage and approximately half of all patients present with unresectable, locally advanced, or metastatic disease.[@b4-ott-9-5663] With a median survival of only 6--8 months, the prognosis for advanced esophageal cancer is extremely poor.[@b5-ott-9-5663] Cytotoxic chemotherapy has been used to control tumor growth, improve life quality, and prolong survival of these patients.[@b6-ott-9-5663] A large number of clinical trials have demonstrated that platinum-, fluoropyrimidine-, and taxane-based regimens are standard and effective chemotherapies.[@b6-ott-9-5663]--[@b8-ott-9-5663] However, the treatment outcomes of these regimens in advanced ESCC were not satisfactory in terms of efficacy or long-term outcome and therapeutic advances significantly lag behind those for other solid tumors such as non-small cell lung carcinoma. Therefore, developing more effective and less cytotoxic chemotherapy regimens has been an urgent task in advanced esophageal cancer.

As a solvent-free formulation of paclitaxel, nanoparticle albumin-bound paclitaxel (nab-PTX, nab-paclitaxel) is developed to avoid the toxicities of polyethoxylated castor oil vehicle used in solvent-based PTX (sb-PTX).[@b9-ott-9-5663] Preclinical models suggest that nab-PTX reaches a tenfold higher peak concentration of free PTX, delivers over 33% drug to tumors, and crosses endothelial cells more efficiently when compared with sb-PTX.[@b10-ott-9-5663],[@b11-ott-9-5663] Based on preclinical evidence, numerous clinical studies have confirmed that nab-PTX has higher tumor retention, lower toxicity, and more potent antitumor effects on breast cancer,[@b12-ott-9-5663] non-small cell lung carcinoma,[@b13-ott-9-5663] pancreatic cancer,[@b14-ott-9-5663] melanoma,[@b15-ott-9-5663] and ovarian cancer, when compared with solvent-based PTX.[@b16-ott-9-5663] Especially, in a study of advanced ESCC patients, the optimal safety and efficacy profile were determined through the application of 250 mg/m^2^ nab-PTX plus cisplatin (DDP) every 3 weeks, which showed an objective response rate (ORR) of 60.6% and a median survival of \>15.5 months when compared with other traditional regimens.[@b17-ott-9-5663] Many clinical studies have shown that weekly administration of PTX is better than a 3-weekly administration, even though the treatment effects are comparable because the incidences of side effects are clearly lower for the weekly administration.[@b18-ott-9-5663]--[@b20-ott-9-5663] In addition, weekly nab-PTX in combination with DDP has been used for locally advanced ESCC, which showed a pathological complete response (CR) rate of 13.3% and a near pathological CR rate of 6.7% in a Phase II study.[@b21-ott-9-5663] Moreover, a Phase II study has shown that weekly PTX plus DDP is an active regimen with excellent tolerability for advanced gastric and gastroesophageal cancer.[@b22-ott-9-5663]

Based on the promising results of the study, the efficacy and safety of weekly nab-PTX plus DDP (nab-TP) administered every 3 weeks were compared with those of weekly sb-PTX plus DDP (sb-TP) administered every 3 weeks in advanced ESCC in this trial.

Materials and methods
=====================

Patient characteristics
-----------------------

From June 2009 to June 2015, 32 (two recurrent) patients with advanced ESCC were treated with the nab-TP regimen as first-line chemotherapy. Another 43 (three recurrent) patients were treated with the sb-TP regimen. Retrieved clinical data included patient's age at diagnosis, disease stage at diagnosis, tumor histology, tumor grade, ethnicity, patient and family cancer history, comorbidities, surgical management, first-line chemotherapy, treatment toxicity, progression-free survival (PFS), overall survival (OS), and status at the most recent follow-up. For patients (aged 18 years or older) with histologically/cytologically confirmed ESCC and unresectable metastatic disease, an Eastern Cooperative Oncology Group performance status of 0--2 and a life expectancy of \>3 months were applied. Adequate hematological (absolute neutrophil count ≥1.5×10^9^/L, platelet count ≥100×10^9^/L, hemoglobin ≥9 g/dL), renal (serum creatinine ≤1.5× the upper limit of normal), and hepatic (total bilirubin ≤2.0 mg/dL and serum transaminase level ≤3× the upper limit of normal) parameters were also required. Prior chemotherapy for advanced disease was not permitted; however, adjuvant or neoadjuvant chemotherapy was allowed on the condition that it was completed at least 6 months before starting first-line therapy. Other key exclusion criteria included: clinically significant cardiovascular disease; concomitant cancers; clinically detectable ascites; neuropathy; parallel radiation therapy; brain or leptomeningeal involvement; and uncontrolled significant comorbid conditions. Before the treatment, written informed consent for chemotherapy drugs, treatment schedule, and toxicity was obtained from all patients. As this was a retrospective study, ethical approval and patient consent were not required, as stated by the medical ethics committee of the Henan Cancer Hospital.

Treatment
---------

For the patients who were assigned to receive nab-TP, nab-PTX was intravenously infused at a dosage of 125 mg/m^2^ on the first and eighth days and DDP was intravenously administered at 75 mg/m^2^ with adequate hydration on the first day of every 21-day cycle. For the patients who were assigned to receive sb-TP, PTX was intravenously infused at a dosage of 80 mg/m^2^ on the first and eighth days (3-hour infusion) and DDP was administered in the same manner on the first day of every 21-day cycle. Approximately 30 minutes before the administration of PTX, patients were premedicated with 20 mg of dexamethasone, 45.5 mg of pheniramine maleate, and 20 mg of famotidine. The efficacy was evaluated for every two cycles. Until disease progression or the occurrence of unacceptable toxicity, patients received chemotherapy for up to six or eight cycles.

Efficacy and toxicity evaluation
--------------------------------

Pretreatment evaluation included a full medical history, physical examination, tumor-related symptoms, complete blood cell count, blood chemistry analysis, creatinine clearance, upper gastrointestinal endoscopies, electrocardiograph, and thoracic and abdominal computed tomographic scans. In addition, toxicities were graded according to the National Cancer Institute of Canada Common Toxicity Criteria (version 2.0).[@b23-ott-9-5663] In accordance with the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines, tumor assessments were carried out by employing chest and abdomen computed tomographic scans every two cycles of therapy.[@b24-ott-9-5663] Responses were confirmed through repeated assessments carried out \<4 weeks apart. After six or eight chemotherapy cycles, patients were monitored for every 12 weeks until disease progression.

Statistical analysis
--------------------

Statistical Package for Social Sciences version 14.0 software (SPSS Inc., Chicago, IL, USA) was adopted to analyze all data. Descriptive variables of patient characteristics and toxicities were directly calculated from the database. In order to compare toxicities and response in the two groups, *χ*^2^ test and Fisher's exact test were employed. Meanwhile, PFS was calculated from the first day of treatment to the date of progressive disease or the date of death from any causes, whereas OS was measured from the initiation of chemotherapy to the date of the last follow-up or death. PFS and OS were calculated and plotted by making use of Kaplan--Meier methods and compared by means of the log-rank test. A *P*-value of \<0.05 (two-sided) was considered to be statistically significant.

Results
=======

Patient characteristics
-----------------------

A total of 32 patients were treated with nab-TP regimen and 43 were treated with sb-TP. The baseline characteristics of the patients treated with nab-TP were similar to those treated with sb-TP ([Table 1](#t1-ott-9-5663){ref-type="table"}). The median age of these patients was 54 years (range: 29--73) and they consisted of 46 males and 29 females. Also, 88% of patients had an Eastern Cooperative Oncology Group performance status of 0--1.

Treatment
---------

The median number of cycles administered was four in the nab-TP arm group (range: 3--8) and five in the sb-TP group (range: 2--8). In total, 14 (43.8%) of the 32 nab-TP treated patients and 23 (53.5%) of the 43 TP-treated patients completed ≥5 cycles of chemotherapy. A total of 149 and 168 cycles were separately administered in the nab-TP and sb-TP arms, respectively. Besides, dose reduction occurred in seven nab-TP patients (22%) and ten sb-TP patients (23%); treatment delay of \>7 days occurred in 12 nab-TP patients (37.5%) and 17 sb-TP patients (40%). A similar proportion of patients received second-line chemotherapy (nab-TP =66%, sb-TP =70%) ([Table 2](#t2-ott-9-5663){ref-type="table"}).

Overall response and survival
-----------------------------

All patients were evaluated for drug efficacy. The ORR and disease control rate (DCR) were 50% and 81% (1 CR, 15 partial response \[PR\], and 10 stable disease \[SD\]), respectively, in the nab-TP group and 30% and 65% (1 CR, 12 PR, and 15 SD), respectively, in the sb-TP group ([Table 3](#t3-ott-9-5663){ref-type="table"}). The nab-TP arm demonstrated a higher ORR (50% vs 30%; *P*=0.082) and DCR (81% vs 65%; *P*=0.124) than the sb-TP group ([Table 3](#t3-ott-9-5663){ref-type="table"}). The median PFS was 6.1 months (95% confidence interval \[CI\]: 5.5--7.1 months) in the nab-TP arm and 5.0 months (95% CI: 4.1--6.1 months) in the sb-TP arm (*P*=0.029) ([Figure 1A](#f1-ott-9-5663){ref-type="fig"}; [Table 4](#t4-ott-9-5663){ref-type="table"}). Furthermore, the median OS was 12.5 months (95% CI: 9.4--15.6 months) for the nab-TP group and 10.7 months (95% CI: 8.1--13.3 months) for the sb-TP group (*P*=0.269) ([Figure 1B](#f1-ott-9-5663){ref-type="fig"}; [Table 4](#t4-ott-9-5663){ref-type="table"}).

In the nab-TP arm, there was an improvement in PFS (median, 6.1 vs 5.0; *P*=0.029). In spite of the favorable OS trend in the nab-TP arm, statistical significance was not reached. Regarding the application of second-line therapy, there were no major imbalances between the treatment groups (nab-TP arm, 66% and sb-TP arm, 70%).

Safety and tolerability
-----------------------

All patients were assessable for toxicity. Grade 3 or higher major treatment-related adverse events are shown in [Table 5](#t5-ott-9-5663){ref-type="table"}. Although the occurrence of the most common grades 3 and 4 leukopenia, neutropenia, febrile neutropenia, and anemia was more frequent in nab-TP, no significant difference was observed between the two groups (all *P*\>0.05). During the entire treatment period, thrombocytopenia was similar in both arms. In general, nonhematologic toxicities were mild and manageable. Significantly less common grade ≥3 peripheral neuropathy, arthralgia, and myalgia occurred in the nab-PC arm (all *P*\<0.05). In either treatment group, no treatment-related deaths occurred.

Discussion
==========

Because of its extremely aggressive nature and poor survival rate, advanced ESCC is one of the least studied and deadliest cancers worldwide.[@b25-ott-9-5663] To date, the National Comprehensive Cancer Network (NCCN) guidelines concerning ESCC are based on the results of various clinical trials that have included a number of patients with gastroesophageal junction or gastric adenocarcinoma due to a relative rarity of enough clinical evidence from randomized Phase III trials for ESCC.[@b26-ott-9-5663],[@b27-ott-9-5663] However, our study is based on a homogenous cohort of advanced ESCC patients, so as to find effective regimens for them.

As far as we know, this is the first comparative study of nab-PTX plus platinum doublet with PTX-DDP. Our findings revealed that the combined therapy of nab-TP regimen was associated with a higher response rate (50% vs 30%) and DCR (81% vs 65%) when compared with sb-TP and no significant difference was observed between them. Nab-TP possessed a longer median PFS (6.1 vs 5.0 months; *P*=0.029) than sb-TP. According to the results of Kaplan--Meier curve analysis, the endpoint tended to be better in nab-TP, although the difference in OS was not statistically significant. Studies demonstrated that the ability to deliver a higher dose of PTX, enhanced tissue distribution, and tumor uptake of nab-PTX versus sb-PTX likely contributed to more favorable efficacy and safety profile of the albumin-bound formulation of PTX.[@b10-ott-9-5663] In general, these findings of sb-TP were comparable with other previously reported studies.[@b17-ott-9-5663],[@b28-ott-9-5663] These findings suggested that nab-TP might become a promising treatment option for ESCC.

In Shi et al's study, a sample of 33 patients without control arm showed a clinically significant response rate (60.6%) and DCR (87.9%), as well as a median PFS of 6.2 months and a longer median OS of 15.5 months, when compared with other traditional taxane-based regimens.[@b17-ott-9-5663] Approximately 87.9% patients who received subsequent treatment after progression may have contributed to better OS.[@b17-ott-9-5663] Although the differences were not statistically significant, another study showed that in advanced esophageal cancer patients, there was a tendency of higher ORR and DCR with nab-PTX-based regimens than with PTX/docetaxel (DTX)-based regimens (25% vs 19.7% and 81.3% vs 59.1%, respectively), in which nab-PTX, PTX, DDP, and 5-FU (TPF), and TP groups were included. Nab-PTX had a tendency to result in longer PFS and OS than TP regimen. Among nab-PTX, TPF, and TP groups, there were no significant differences in ORR, PFS, and OS.[@b28-ott-9-5663] With an ORR of 37.0%, a DCR of 44.4%, and a median PFS of 6.6 months, the outcome of second-line chemotherapy with nab-PTX was reported to show promising efficacy in advanced ESCC by Yuan et al.[@b29-ott-9-5663]

With lower rates of grades 3 and 4 neuropathy, arthralgia, and myalgia, nab-TP was generally better tolerated (all *P*\<0.05). The relief of neuropathy-associated symptom burden may be considered when making decisions on chemotherapy options.[@b30-ott-9-5663] Neuropathy is irreversible with PTX in some patients, which has been attributed to the excipient cremophor.[@b31-ott-9-5663],[@b32-ott-9-5663] Although a higher percentage of patients in the nab-TP arm developed anemia, febrile neutropenia, leukopenia, and neutropenia, this difference was not statistically significant. Dose reduction (22% vs 23%; *P*=0.88) and treatment delays (37.5% vs 40%; *P*=0.86) were similar in the two regimens. The safety profile for both regimens was consistent with that in previous reports.[@b17-ott-9-5663],[@b28-ott-9-5663],[@b29-ott-9-5663] When compared with sb-TP, the rate of serious life-threatening adverse events was not increased with the application of nab-TP. Adverse events were generally grade 3 or lower and resolved without specific treatment. But the occurrence of neutropenia, febrile neutropenia, and thrombocytopenia was greater in this study than with 3-weekly nab-TP with DDP as reported by Shi et al.[@b17-ott-9-5663] Two additional cycles may have contributed to increased bone marrow suppression in our study (six to eight chemotherapy cycles) when compared to Shi et al's trial (four to six chemotherapy cycles).

Limitations
===========

There are some limitations in this study. First of all, it was a retrospective study performed at a single institution. Second, the follow-up schedule for the two treatment regimens was not identical because nab-TP-treated patients were followed more closely and evaluated weekly for toxicity. Therefore, there was a possible underestimation of bone marrow toxicity in the sb-TP group since midcycle bone marrow toxicity might not have been reported in the sb-TP group. Another limitation of the study was that life quality was not measured.

Conclusion
==========

Advanced ESCC patients had a higher ORR and DCR with the administration of nab-TP versus sb-TP as a first-line therapy. Significant improvement was observed in favor of the nab-TP arm for PFS. When compared with sb-TP, nab-TP produced less severe neuropathy, myalgia, and arthralgia. Taken together, the nab-TP regimen has a more favorable risk--benefit profile than that of sb-TP as a first-line therapy for all advanced ESCC patients.
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###### 

Baseline characteristics of the patients

  Baseline characteristics     Nab-paclitaxel plus DDP (n=32)   Solvent-based paclitaxel plus DDP (n=43)   *P*-value (*χ*^2^)
  ---------------------------- -------------------------------- ------------------------------------------ --------------------
  Age, years                                                                                               
   Median                      52                               56                                         
   Range                       29--71                           34--73                                     
    \<65                       27 (84%)                         34 (79%)                                   0.560
    ≥65                        5 (16%)                          9 (21%)                                    
  Sex                                                                                                      0.764
   Male                        19 (59%)                         27 (63%)                                   
   Female                      13 (41%)                         16 (37%)                                   
  ECOG performance status                                                                                  0.546
   0--1                        29 (91%)                         37 (86%)                                   
   2                           3 (9%)                           6 (14%)                                    
  Tumor grade                                                                                              0.830
   Poor differentiated         12 (38%)                         19 (44%)                                   
   Moderate differentiated     15 (47%)                         11 (26%)                                   
   Well differentiated         3 (9%)                           10 (23%)                                   
   Unknown                     2 (6%)                           3 (7%)                                     
   Subsequent treatment        27 (84%)                         38 (88%)                                   
  Number of metastatic sites                                                                               0.755
   1                           13 (41%)                         17 (40%)                                   
   2                           9 (28%)                          16 (37%)                                   
   ≥3                          10 (31%)                         10 (23%)                                   

**Abbreviations:** DDP, cisplatin; ECOG, Eastern Cooperative Oncology Group; nab, nanoparticle albumin-bound.

###### 

Overall treatment summary

  --------------------------------------------------------------------------
  Treatment administration                Nab-TP\     Sb-TP\     *P*-value
                                          (n=32)      (n=43)     
  --------------------------------------- ----------- ---------- -----------
  Median number of cycles (range)         4 (3--8)    5 (2--8)   

  Dose reduction, patients (%)            7 (22)      10 (23)    0.888

  Cycle delays (\>7 days), patients (%)   12 (37.5)   17 (40)    0.858

  Second-line chemotherapy (%)            21 (66)     30 (70)    0.704
  --------------------------------------------------------------------------

**Abbreviations:** nab-TP, nanoparticle albumin-bound paclitaxel with cisplatin; sb-TP, solvent-based paclitaxel with cisplatin.

###### 

Overall response to treatment

  Tumor response        Nab-paclitaxel plus DDP (n=32)   Paclitaxel + DDP (n=43)   *P*-value
  --------------------- -------------------------------- ------------------------- -----------
  Complete response     1 (3)                            1 (2)                     
  Partial response      15 (47)                          12 (28)                   
  Stable disease        10 (31)                          15 (35)                   
  Progressive disease   6 (19)                           15 (35)                   
  ORR                   16 (50)                          13 (30)                   0.082
  DCR                   26 (81)                          28 (65)                   0.124

**Abbreviations:** DDP, cisplatin; nab, nanoparticle albumin-bound; ORR, objective response rate; DCR, disease control rate.

###### 

Kaplan--Meier analysis

  Survival      Nab-paclitaxel plus DDP median (95% CI)   Paclitaxel + DDP median (95% CI)   *P*-value (log-rank test)
  ------------- ----------------------------------------- ---------------------------------- ---------------------------
  PFS, months   6.0 (4.4--7.6)                            5.1 (4.29--5.91)                   0.091
  OS, months    12.5 (9.4--15.6)                          10.7 (8.1--13.3)                   0.269

**Abbreviations:** CI, confidence interval; DDP, cisplatin; nab, nanoparticle albumin-bound; OS, overall survival; PFS, progression-free survival.

###### 

Toxicity profile

  Toxicity                    Number of patients, n (%)   *P*-value (*χ*^2^)                     
  --------------------------- --------------------------- -------------------- -------- -------- -------
  Hematological toxicity                                                                         
   Leukopenia                 7 (22)                      5 (16)               8 (19)   5 (12)   0.499
   Neutropenia                8 (25)                      4 (13)               9 (21)   3 (7)    0.348
   Febrile neutropenia        4 (13)                      2 (6)                3 (7)    3 (7)    0.717
   Thrombocytopenia           5 (16)                      1 (3)                6 (14)   2 (5)    0.932
   Anemia                     7 (22)                      2 (6)                7 (16)   2 (5)    0.478
  Nonhematological toxicity                                                                      
   Anorexia                   4 (13)                      0                    5 (12)   0        0.909
   Nausea/vomiting            2 (6)                       0                    3 (7)    0        0.900
   Diarrhea                   2 (6)                       0                    1 (2)    1 (2)    0.785
   Stomatitis                 0                           0                    0        0        0.765
   Peripheral neuropathy      0                           0                    4 (9)    0        0.036
   Myalgia                    0                           0                    5 (12)   0        0.018
   ALT/AST                    0                           0                    0        0        0.460
   Creatinine                 0                           0                    0        0        0.991
   Arthralgia                 0                           0                    4 (9)    0        0.036
   Fatigue                    0                           0                    3 (7)    0        0.073

**Abbreviations:** ALT/AST, alanine transaminase/aspartate transaminase; nab-TP, nanoparticle albumin-bound paclitaxel with cisplatin; sb-TP, solvent-based paclitaxel with cisplatin.
